Other figures show the economic impact of diabetes. According to figures supplemented in March 2013, the total costs of diabetes in the United States in 2012 was $245 billion, of which $176 billion was classified as direct medical costs and $69 billion classified as costs arising from diabetics’ reduced quality of life. After they made adjustments for population and sex differences, researchers found that people with diagnosed diabetes spent 2.3 times more on medical expenditures than those without diabetes.
In other words, it’s clear that diabetes is a well-entrenched health risk in just America alone. With leading diabetes complications such as heart disease and high blood pressure on the rise, the need for effective therapeutic treatment as well preventive measures is becoming increasingly more mainstream and compelling.
Boston Therapeutics, billing itself as “a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes,” is working to develop a solution that exhibits potential in being a pioneering solution to the ever-growing diabetes outbreak. That solution is namely the company’s PAZ320, a non-systemic, non-toxic, chewable drug for prevention of diabetes and its complications. This polysaccharide targets enzymes that digest sugar during digestion, thereby reducing the amount of available glucose for the intestine to absorb. This capability positions the PAZ320 as a prospective solution for slowing the onset of Type 2 diabetes and/or the development of diabetes complications (e.g., heart disease, stroke, kidney damage, retinopathy, and Diabetic Foot).
In addition to exhibiting strong potential in its R & D efforts, Boston Therapeutics is also led by a highly experienced and successful management and scientific advisory team with lengthy expertise in complex carbohydrate chemistry, regulatory, and clinical development. The team’s members have had numerous marked successes in submitting and obtaining approval for multiple drug candidates to the U.S. Food and Drug Administration. Collectively Boston Therapeutics’ executive management team has more than 100 years of combined experience of c-level executive leadership, corporate finance and company operations finessing, bio-medical product innovation, and corporate consulting, among other field focuses.
To illustrate Boston Therapeutics’ leadership expertise, consider Dr. David Platt, chairman, CEO, CFO and company director. He is a world-renowned expert in carbohydrate chemistry and has founded three publicly held companies, generating almost $1 billion for shareholders in those enterprises. He has also led two drug candidates from concept to human clinical trials.
With a strongly experienced management and medical science advisory board behind its efforts, and the strong potential that its PAZ320 might hold for treating diabetes, Boston Therapeutics is positioned at the threshold of delivering one of the most far-reaching innovations in bio-medical solutions in decades, and enjoying the strong profitability that would come with such an accomplishment.
For more information visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment